EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Management of postmenopausal osteoporosis

Ian R Reid iD, Mark J Bolland iD

Endocrine Reviews · 15.07.2026 · 47 (4) · 468-495

DOI: 10.1210/endrev/bnag006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 26.02.2026. Verfasst von Ian R Reid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Auckland, Auckland 1142, New Zealand. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postmenopausal women experience ongoing loss of bone mass, with resulting increases in the risk of fracture. This review describes the nature of postmenopausal bone loss, the definition of osteoporosis, and the current status of fracture risk estimation, which is pivotal in osteoporosis management. Important lifestyle measures include taking a balanced diet to maintain a healthy weight throughout life, safe physical activity, not smoking, and moderating alcohol intake. Severe vitamin D deficiency accelerates bone loss so should be avoided. Falls prevention becomes increasingly important with age, since falls cause most fractures. Pharmaceuticals to increase bone mass and prevent fractures either act by inhibiting bone resorption or by stimulating bone formation. Bisphosphonates are the most widely used antiresorptives, often taken as weekly oral doses. The intravenous bisphosphonate, zoledronate, has a long duration of action with effects on bone turnover, density, and fractures over a decade after a single dose. It is increasingly used in both prevention and treatment of osteoporosis. Denosumab is effective in preventing fractures but has a rapid offset of effect after its cessation. Some anabolic agents act via the PTH1 receptor, producing substantial increases in spine bone density but are not yet proven to prevent hip fractures. Romosozumab is a monoclonal antibody directed at sclerostin. It has both anabolic and antiresorptive effects and shows broad antifracture efficacy. Anabolics are used for 1 to 2 years in those with high fracture risk, before transition to long-term antiresorptive therapy. Treatment sequence options are discussed but more research is needed to establish which provide optimal fracture reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalBone Density Conservation AgentsHumansFemaleDiphosphonates

Stichwörter der Autor:innen

bisphosphonatesdrug treatmentfractureosteopeniaosteoporosis

Substanzen

Bone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Department of Medicine, University of Auckland, Auckland 1142, New Zealand.

ORCID-Profile: Ian R Reid, Mark J Bolland

Zitieren

APA

Reid, I. R., & Bolland, M. J. (2026). Management of postmenopausal osteoporosis. Endocrine Reviews, 47(4), 468-495. https://doi.org/10.1210/endrev/bnag006

Vancouver

Reid IR, Bolland MJ. Management of postmenopausal osteoporosis. Endocrine Reviews. 2026;47(4):468-495. doi:10.1210/endrev/bnag006

BibTeX
@article{Reid2026,
  author = {Reid, Ian R and Bolland, Mark J},
  title = {Management of postmenopausal osteoporosis},
  journal = {Endocrine Reviews},
  year = {2026},
  volume = {47},
  number = {4},
  pages = {468--495},
  doi = {10.1210/endrev/bnag006}
}
Kostenlos starten →